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Abstract
The Mdm2-p53 tumor suppression pathway plays a vital role in regulating cellular homeostasis by integrating a variety of
stressors and eliciting effects on cell growth and proliferation. Recent studies have demonstrated an in vivo signaling
pathway mediated by ribosomal protein (RP)-Mdm2 interaction that responds to ribosome biogenesis stress and evokes a
protective p53 reaction. It has been shown that mice harboring a Cys-to-Phe mutation in the zinc finger of Mdm2 that
specifically disrupts RP L11-Mdm2 binding are prone to accelerated lymphomagenesis in an oncogenic c-Myc driven mouse
model of Burkitt’s lymphoma. Because most oncogenes when upregulated simultaneously promote both cellular growth
and proliferation, it therefore stands to reason that the RP-Mdm2-p53 pathway might also be essential in response to
oncogenes other than c-Myc. Using genetically engineered mice, we now show that disruption of the RP-Mdm2-p53
pathway by an Mdm2
C305F mutation does not accelerate prostatic tumorigenesis induced by inactivation of the pRb family
proteins (pRb/p107/p130). In contrast, loss of p19Arf greatly accelerates the progression of prostate cancer induced by
inhibition of pRb family proteins. Moreover, using ectopically expressed oncogenic H-Ras we demonstrate that p53
response remains intact in the Mdm2
C305F mutant MEF cells. Thus, unlike the p19Arf-Mdm2-p53 pathway, which is
considered a general oncogenic response pathway, the RP-Mdm2-p53 pathway appears to specifically suppress
tumorigenesis induced by oncogenic c-Myc.
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Introduction
p53 is a critical tumor suppressor gene which is mutated in
about 50%of all human tumors [1]. It is often referred to as the
guardian of the genome because under various cellular stress
conditions such as DNA damage, oncogenic insult, and hypoxia,
p53 is stabilized and activated, inducing cell cycle arrest, apoptosis,
DNA damage repair, senescence, and a variety of other protective
responses [2]. Under normal conditions, p53 levels are kept low,
mainly through inhibition by Mdm2 (mouse double minute 2).
The C-terminus of Mdm2 has an intrinsic E3 ligase activity, which
promotes the ubiquination and degradation of p53. The N-
terminus of Mdm2 binds to the transactivation domain of p53 and
inhibits the recruitment of co-activators. Mdm2 is also directly
transactivated by p53, therefore forming an Mdm2-p53 feedback
loop to maintain cellular homeostasis [3].
Recently several ribosomal proteins, including L11 [4], L5 [5]
and L23 [6,7] have been shown to bind Mdm2 at its zinc finger
domain. Under normal conditions, these proteins, along with
rRNAs, form the large and small subunits of ribosomes in the
nucleolus [8]. However, under conditions of ribosome stress, free
forms of ribosomal proteins are released into the nucleoplasm and
bind to Mdm2, leading to p53 stabilization and activation [9]. A
cancer-associated cysteine-to-phenylalanine point mutation in the
zinc finger domain of Mdm2 causes disruption of L11 and L5
binding to Mdm2 [10], and based on this in vitro data, we
previously generated a knock-in mouse with the Mdm2 C305F
mutation. Mdm2
C305F mutant mice maintain a normal p53
response to DNA damage, but are deficient in p53 induction in
response to induced ribosomal stress [11].
Intriguingly, the Mdm2 C305F mutation was recently shown to
significantly accelerate B cell lymphomagenesis in an Em-Myc
induced mouse model of B cell lymphoma [11]. The ability of Myc
to promote cell growth and proliferation is closely linked to its role
in regulating ribosomal biogenesis. Myc facilitates the recruitment
of Pol I to rDNA promoters [12,13], promotes the transcription of
ribosomal proteins by activating Pol II [14,15,16,17], and activates
Pol III-mediated transcription of 5S rRNA and tRNA [18]. In the
case of Em-myc-induced lymphoma, ribosomal proteins L11 and
L5 are unable to bind and suppress Mdm2
C305F in Em-
Myc;Mdm2
C305F/C305F mice, and as a result activation of p53 is
attenuated and B cell lymphomagenesis is accelerated [11]. These
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barrier to Myc-induced tumorigenesis.
Another well-studied pathway suppressing Myc-induced B cell
lymphoma is ARF-Mdm2-p53 signaling. Loss of p19Arf results in
a similar acceleration of Em-Myc induced lymphomagenesis to that
caused by Mdm2 C305F mutation [11,19]. ARF can physically
interact with and inhibit Mdm2, therefore releasing p53 from
Mdm2-mediated degradation and transactivation silencing
[20,21,22,23]. Besides Myc, ARF can also induce p53 in response
to E2F1 and Ras. E2F1 directly activates human p14ARF at the
transcriptional level [24]. Overexpression of Ras transforms
p19Arf-null mouse embryo fibroblasts (MEFs) via bypassing p53-
mediated checkpoint control [25]. Ras also induces cell cycle
arrest in wild-type murine keratinocytes, which is mediated by
increased expression of p19Arf [26]. While ARF-Mdm2-p53
signaling acts downstream of a variety of oncogenes, ARF-
independent induction of p53 can also occur upon oncogenic
stress. For instance, when expressing T121, a transgene inhibiting
pRb and therefore activating E2F1, in choroid plexus (CP)
epithelial cells, p19Arf is dispensable for p53-mediated tumor
suppression and apoptosis [27]. Ras induction of p53-dependent
cell cycle arrest in murine keratinocytes also does not rely on ARF
[28]. The alternative pathway leading to p53 activation is unclear.
Given that oncogenes promote cell proliferation and/or growth
associated with elevated protein synthesis, ribosomal biogenesis
might be generally disrupted in response to oncogenic stress.
Therefore, RP-Mdm2-p53 signaling may play a general role in
responding to oncogenic stress and suppressing tumorigenesis like
it does in Myc-induced B cell lymphoma.
E2F1 has been reported to bind the promoters of rRNA and
enhance its activity [29]. Similarly, in the yeast Saccharomyces
cerevisiae, Ras/TOR induces Sfp1 (zinc finger-containing tran-
scription factor), which activates RP gene expression, a network
linking cell growth to ribosomal biogenesis [30]. In mammalian
cells, Ras-PI3K-Akt-mTOR signaling pathway is well-known to
promote protein translation and cell growth [31]. Upregulation of
these cellular processes may induce ribosomal stress, leading to
activation of RP-Mdm2-p53 signaling. Hence, the current study
focuses on examining whether the RP-Mdm2-p53 pathway may
act as a general response to oncogenic stress by utilizing models of
pRb inactivation and Ras activation.
Specifically, to investigate whether disruption of RP-Mdm2-p53
signaling by Mdm2
C305F mutation accelerates tumorigenesis
induced by inactivation of pRb, we crossed Mdm2
C305F mice with
the well-characterized APT121 mouse prostate cancer model, in
which a truncated SV40 large T antigen (consisting of the first 121
N-terminal amino acids; T121) controlled by the probasin
promoter leads to pRb inactivation in prostate epithelium to
induce prostate cancer [32,33]. To investigate whether disruption
of RP-Mdm2-p53 signaling accelerates tumorigenesis induced by
Ras activation, we used mouse keratinocyte and mouse embryonic
fibroblast systems to measure Ras-induced ribosomal protein levels
and p53 response signaling.
Results
Mdm2 C305F mutation causes reduced prostate size and
slows the progression of APT121-induced prostate cancer
Inactivation of p53 alone in the murine prostate leads to the
development of prostatic intraepithelial neoplasia (PIN) with no
progression to invasive carcinoma, suggesting that loss of p53 may
be a complementary rather than initiating event in promoting
prostate tumorigenesis [34]. Previous findings have also shown
that attenuation of p53 signaling through loss of one allele of p53
does not accelerate the onset of epithelial tumors in an APT121-
induced mouse model of prostate cancer, but induces a stromal
tumor phenotype, which is characterized by extensive stromal cell
presence and intraductal growth patterns [35]. The Mdm2 C305F
mutation, which disrupts the binding of ribosomal proteins L11
and L5 to Mdm2 [11], causes an attenuation of p53 signaling,
suggesting that the Mdm2 C305F mutation may alter the
progression, rather than initiation, of prostate tumorigenesis in a
similar way as p53 heterozygosity.
To examine the importance of the RP-Mdm2-p53 pathway in
APT121-induced prostate cancer, we generated APT121;Mdm2
+/+
and APT121;Mdm2
C305F/C305F mice and non-tumorigenic control
Mdm2
+/+ and Mdm2
C305F/C305F mice. The progression of tumor-
igenesis was then compared among these mice to see if disruption
of RP-Mdm2-p53 signaling altered the development of cancer.
APT121;Mdm2
+/+ and APT121;Mdm2
C305F/C305F mice did not
exhibit noticeable differences in general appearance or body
weight. We compared the size of prostate glands isolated from
mice at 6 months of age. Surprisingly, the prostates from
Mdm2
C305F/C305F mice were generally smaller than those from
Mdm2
+/+ mice, and consistent with this finding, the prostates from
APT121;Mdm2
C305F/C305F mice were smaller than those from
APT121;Mdm2
+/+ mice (Figure 1A). The average weight of 11
Mdm2
C305F/C305F prostates was 0.088 grams while that of 12
Mdm2
+/+ prostates was 0.117 grams. The average weight of 13
APT121;Mdm2
C305F/C305F prostates was 0.172 grams and that of 9
APT121;Mdm2
+/+ prostates was 0.221 grams (Figure 1B). The
differences in weight were statistically significant, with *p,0.05
and **p,0.01 respectively.
We next examined prostate histology by hematoxylin and eosin
(H&E) staining on paraffin-embedded prostate samples isolated
from 6 month-old mice. None of the Mdm2
C305F/C305F or Mdm2
+/+
mice exhibited abnormality in their prostates (Figure 1C). Prostate
adenocarcinoma, defined as penetration of malignant prostate
epithelial cells through the basement membrane of the prostate
gland into the surrounding stroma, was often observed in
APT121;Mdm2
+/+ mice, while the majority of the
APT121;Mdm2
C305F/C305F mice only developed mPIN (mouse
prostatic intraepithelial neoplasia), with few examples of well-
differentiated adenocarcinoma (Figure 1C ). As shown in Table 1,
71.4%of APT121;Mdm2
+/+ mice developed adenocarcinomas
compared with only 37.5%of APT121;Mdm2
C305F/C305F mice. Thus
the progression from mPIN to adenocarcinoma is decreased by
Mdm2
C305F mutation.
Mdm2 C305F mutation decreases proliferation but does
not affect apoptosis of APT121-induced prostate cancer
To address the differences in tumor progression described
above, the proliferation and apoptosis of isolated prostate tissues
were examined by immunohistochemical analysis. Cell prolifera-
tion was assessed by ki67 staining. Prostates from Mdm2
C305F/C305F
or Mdm2
+/+ mice had few proliferating cells, while prostates from
APT121;Mdm2
+/+ and APT121;Mdm2
C305F/C305F mice were highly
proliferative (Figure 2A). As quantified in Figure 2B, there was no
statistically significant difference in the percentage of ki67 positive
cells between Mdm2
+/+ and Mdm2
C305F/C305F prostates (3.64%and
3.39%, respectively). However, there was a statistically significant
difference in the percentage of ki67 positive cells between
APT121;Mdm2
+/+ and APT121;Mdm2
C305F/C305F prostates
(64.6%and 48.8%, respectively).
To examine apoptosis in the prostates of the various transgenic
mice, TUNEL (terminal deoxynucleotidyl transferase–mediated
dUTP-biotin nick end labeling) immunohistochemical analysis was
carried out. Representative pictures of TUNEL-stained sections
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+/+
and APT121;Mdm2
C305F/C305F mice had a much higher percentage
of TUNEL-positive apoptotic cells than those of Mdm2
+/+ or
Mdm2
C305F/C305F mice (Figure 2D). However, there was no
significant difference in apoptosis between APT121;Mdm2
+/+ and
APT121;Mdm2
C305F/C305F prostates (5.59%and 6.51%respectively)
or between Mdm2
+/+ and Mdm2
C305F/C305F prostates (0.29%and
0.89%respectively). Taken together, these data suggest that the
Mdm2
C305F mutation may slow down the progression of prostate
tumorigenesis by decreasing proliferation, rather than affecting the
apoptosis of prostatic cells.
Previous studies have shown that Myc can up-regulate
ribosomal biogenesis [12,13] and that ribosomal protein expres-
sion is elevated during Myc-induced lymphomagenesis [11]. To
investigate whether APT121 induces increased expression of
ribosomal proteins, total protein was isolated from prostate glands
harvested from four mice of each genotype, and expression of
ribosomal protein L11 was examined by western blot. Unlike the
Figure 1. Mdm2 C305F mutation causes reduced prostate size and slows the progression of APT121-induced prostate cancer. A.
Photographs showing representative prostates from 6 month-old mice of the indicated genotypes. B. Average prostate mass 6 SD from 6 month-old
mice of the indicated genotypes. Mdm2
+/+ (n=12), Mdm2
C305F/C305F (n=11), APT121;Mdm2
+/+ (n=9), and APT121;Mdm2
C305F/C305F (n=13) . * p,0.05 and
** p,0.01 as assessed by Student’s t test. C. Representative H&E staining of prostate sections from 6 month-old mice of the indicated genotypes
demonstrating histology associated with the indicated stages of tumor progression. Scale bar was shown in the first picture and all pictures were
taken at the same magnification.
doi:10.1371/journal.pone.0021625.g001
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significantly increased in the presence of Myc [11], L11 was not
induced by APT121 (data not shown), suggesting that APT121-
induced prostate cancer does not cause ribosomal stress.
Loss of p19Arf accelerates adenocarcinoma and stromal
tumor development in APT121-induced prostate cancer
While our data suggest that RP-Mdm2 signaling does not
inhibit APT121-induced prostate cancer, previous findings have
shown that both RP-Mdm2 and p19Arf-Mdm2 signal to p53 and
function equivalently as barriers to suppress Myc-induced B cell
lymphoma [11,19]. ARF can be induced by a variety of oncogenes
including Ras, Myc and E2F1, inhibiting Mdm2 and thereby
activating p53 [24,36,37]. p53 is believed to play an important role
in suppressing prostate cancers of higher tumor stage or androgen-
independent tumors [38,39]. However, it is unknown whether
p19Arf-Mdm2-p53 signaling is needed for the suppression of
APT121-induced prostate cancer.
To examine the role of the p19Arf-Mdm2-p53 pathway in
APT121-induced prostate cancer, we crossed APT121 with p19Arf-
null mice. By 5 months of age, all APT121;p19Arf
2/2 mice
developed adenocarcinomas, while the majority of the APT121;-
p19Arf
+/+ mice only developed mPIN (Table 2). Furthermore,
tumors from APT121;p19Arf
2/2 prostates were comprised of a
large portion of stromal cells, which expanded not only outside of
the epithelial glands, but inside the glands as well (Figure 3A). This
phenotype was similar to what was defined as ‘stromal tumor’ in a
previous study [35]. The stromal tumor phenotype occurred at a
high frequency (5 of 6 mice) in APT121;p19Arf
2/2 mice while it was
not detected in APT121;p19Arf
+/+ mice (Table 2).
We further measured the proliferation and apoptosis rates of
APT121;p19Arf
+/+ and APT121;p19Arf
2/2 prostates by immunohis-
tochemical analysis as mentioned above. APT121;p19Arf
2/2
prostates exhibited a higher rate of proliferation and no significant
difference in apoptosis compared with APT121;p19Arf
+/+ prostates
(Figure 3B–C and 3D–E). Therefore, p19Arf-Mdm2-p53 signaling
apparently inhibits the progression of APT121-induced prostate
cancer by affecting cell proliferation. Taken together, these data
suggest that the p19Arf-Mdm2-p53 pathway, rather than the RP-
Mdm2-p53 pathway, is the main barrier to suppress APT121-
induced prostate cancer.
Activated Ras does not up-regulate the expression of
ribosomal protein in mouse keratinocytes
To further investigate if the RP-Mdm2-p53 signaling pathway is
required for oncogenic Ras induction of p53, we examined its
function in response to activation of H-Ras. Constitutively active
mutant forms of the Ras family of small GTPases are found in
approximately one-third of all human cancers. Active GTP-bound
Ras stimulates numerous effector proteins to induce diverse
downstream signaling events affecting cell growth, proliferation,
differentiation, and apoptosis [40]. Given that the Ras-PI3K-Akt-
mTOR pathway promotes protein translation and cell growth in
mammalian cells [41], we tested whether activated Ras could
induce ribosomal stress and trigger the RP-Mdm2-p53 pathway.
To investigate this possibility, we first examined whether Ras
could up-regulate the expression of ribosomal proteins in four
different mouse keratinocyte cell lines: BalMk2 normal mouse
keratinocytes with wild-type Ras, 308 benign mouse skin
papilloma cells [42], CH72-T3 malignant mouse skin squamous
cell carcinoma cells [43], and CC4A malignant mouse skin
carcinoma cells all carrying an H-Ras mutation at codon 61 [44].
We measured the protein level of ribosomal protein L11 by
western blot. Compared with BalMK2 normal mouse keratino-
cytes that have wild-type Ras, Ras activation in 308, CH72-T3 or
CC4A cell lines did not induce increased expression of ribosomal
protein L11 (Figure 4A).
Expression of activated Ras in Mdm2
C305F mutant MEFs
induces a normal p53 response but does not up-regulate
the expression of ribosomal proteins
While the data from mouse keratinocytes suggested that
activated Ras may not induce ribosomal stress, the cell lines could
not fully address the function of RP-Mdm2-p53 signaling in
response to Ras activation. In order to investigate whether the
Mdm2
C305F mutant protein, and thus decreased interaction
between ribosomal proteins and Mdm2, could affect the p53
response to Ras activation, early passage Mdm2
+/+ and
Mdm2
C305F/C305F MEFs were stably infected with retroviruses
encoding either H-Ras
G12V (a constitutively active form of H-Ras)
or an empty vector control. Ras is known to induce cellular
senescence via an intact p19Arf-Mdm2-p53 pathway in murine
cells [25,36]. Following infection with Ras virus, we observed
comparable cell cycle arrest in Mdm2
+/+ and Mdm2
C305F/C305F
MEFs as evidenced by a similar decrease in cell number
(Figure 4B). Ras expression was confirmed by western blot
analysis and was comparable in Mdm2
+/+ and Mdm2
C305F/C305F
MEFs (Figure 4C).
To determine the effect of Ras expression on ribosomal protein
levels, cell lysates were immunoblotted for expression of L5 and
L11. Expression of activated Ras did not upregulate L11 or L5 in
Mdm2
C305F/C305F or Mdm2
+/+ MEFs (Figure 4C, lane 1 versus lane
2, lane 3 versus lane 4). To examine p53 response to Ras
expression, cell lysates were also immunoblotted for p53. Ras
induced p53 stabilization in both Mdm2
C305F/C305F and Mdm2
+/+
MEFs (Figure 4C, lane1 versus lane2, lane 3 versus lane4). p53 was
induced to a similar extent in Mdm2
C305F/C305F and Mdm2
+/+
MEFs (Figure 4C, lane2 versus lane4), indicating that Mdm2
C305F/
Table 1. Summary of prostate tumor stages in 6 month-old Mdm2
+/+, Mdm2
C305F/C305F, APT121;Mdm2
+/+ ,a n dAPT121; Mdm2
C305F/C305F
mice.
Mdm2
+/+ Mdm2
C305F/C305F APT121;Mdm2
+/+ APT121; Mdm2
C305F/C305F
Total 8 7 7 8
Normal 8 7 0 0
Dysplasia 0 0 0 0
mPIN 0 0 2 5
Adenocarcinoma 0 0 5 (71.4%) 3 (37.5%)
doi:10.1371/journal.pone.0021625.t001
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data suggest that Ras activation does not induce ribosomal stress in
the cells tested, and that RP-Mdm2-p53 signaling may not be
critical in response to Ras-induced oncogenic stress.
Discussion
Recently several ribosomal proteins, including L11 [4], L5 [5]
and L23 [6,7] have been shown to bind Mdm2 at its zinc finger
domain. Under conditions of ribosomal stress, free forms of
ribosomal proteins are released into the nucleoplasm and bind to
Mdm2, leading to p53 stabilization and activation [9]. Interest-
ingly, a cancer-associated cysteine-to-phenylalanine point muta-
tion in the zinc finger domain of Mdm2 disrupts binding of L11
and L5 to Mdm2 [10], and Mdm2
C305F mutant knock-in mice are
deficient in p53 induction in response to induced ribosomal stress
[11].
Additionally, the Mdm2 C305F mutation was recently shown to
significantly accelerate B cell lymphomagenesis in an Em-Myc
induced mouse model of B cell lymphoma [11,45]. The ability of
Myc to promote cell growth and proliferation is closely linked to its
role in regulating ribosomal biogenesis, and in the case of
Figure 2. Mdm2 C305F mutation decreases proliferation but does not affect apoptosis of APT121-induced prostate cancer. A.
Representative Ki67 staining of prostate sections from 6 month-old mice of the indicated genotypes. Brown staining indicates proliferating cells. Scale
bar was shown in the first picture and all pictures were taken at the same magnification. B. Average%Ki67-positive cells 6 SD from 6 month-old mice
of the indicated genotypes. At least five independent fields consisting of a total of at least 1,000 cells from each prostate sample were counted.
**p,0.01 as assessed by Student’s t test. C. Representative TUNEL staining of prostate sections from 6 month-old mice of the indicated genotypes.
Brown staining indicates apoptotic cells. Scale bar was shown in the first picture and all pictures were taken at the same magnification. D.
Average%TUNEL-positive cells 6 SD from 6 month-old mice of the indicated genotypes. At least five independent fields consisting of a total of at
least 1,000 cells from each prostate sample were counted. (A–D) Mdm2
+/+ (n=8), Mdm2
C305F/C305F (n=7), APT121;Mdm2
+/+ (n=7), and
APT121;Mdm2
C305F/C305F (n=9) mice were used.
doi:10.1371/journal.pone.0021625.g002
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C305F and Myc-induced lymphoma, ribosomal protein
expression is elevated, however ribosomal proteins L11 and L5
are unable to bind and suppress Mdm2
C305F, resulting in
attenuation of p53 activation [11]. These findings established the
RP-Mdm2-p53 pathway as a genuine barrier to Myc-induced
tumorigenesis.
The current study examined whether the RP-Mdm2-p53
pathway acts as a general response to oncogenic stress by utilizing
models of pRb inactivation and Ras activation. We now show that
Mdm2 C305F mutation results in decreased prostate size and,
unlike the situation in Myc-induced B cell lymphomagenesis [11],
slows the progression of prostate tumorigenesis induced by
inactivation of pRb family proteins in the well-characterized
APT121 mouse model of prostate cancer [32]. Immunohistochem-
ical analysis showed a significant decrease in the percentage of
ki67-positive cells in prostates isolated from APT121;Mdm2
C305F/
C305F versus APT121;Mdm2
+/+ mice, but no significant difference in
TUNEL staining. These data suggest that the reduction in prostate
size and slowed progression of prostate tumorigenesis induced by
Mdm2 C305F mutation may be due to a defect in proliferation
rather than an increase in cell death. Moreover, unlike the
situation in Myc-induced lymphomagenesis in which ribosomal
protein L11 expression was significantly increased [11], L11
expression was not induced by APT121 (data not shown), suggesting
that APT121-induced prostate cancer does not cause ribosomal
stress. While Mdm2
C305F/C305F mice exhibit smaller prostates than
wild-type mice, the prostates from Mdm2
C305F/C305F mice are
normal in function and do not have developmental defects. p53
has recently been reported to promote cell survival through
induction of TIGAR (TP53-induced glycolysis and apoptosis
regulator) [46]. It is possible that disruption of RP-Mdm2-p53
signaling leads to a slightly lower level of p53 in the Mdm2
C305F/
C305F prostates. Under normal conditions, the slight difference in
p53 level may not be critical for cell proliferation and growth,
however, under oncogenic stress such as pRb inhitition, lower p53
levels may hinder cell proliferation in the Mdm2
C305F/C305F
prostates.
With regard to Ras activation, we show that constitutively active
mutant Ras does not up-regulate the expression of ribosomal
proteins either in mouse keratinocyte cell lines or when
overexpressed in Mdm2
+/+ or Mdm2
C305F/C305F MEFs. These data
suggest that Ras activation does not induce ribosomal stress in the
cells tested, and that RP-Mdm2-p53 signaling may not be critical
in response to Ras-induced oncogenic stress.
While previous findings have shown that both RP-Mdm2 and
p19Arf-Mdm2 signal to p53 and similarly suppress Myc-induced B
cell lymphoma [11,19], our data presented here suggest that
disruption of RP-Mdm2 signaling does not accelerate APT121-
induced prostate cancer. However, loss of p19Arf accelerates
adenocarcinoma and stromal tumor development in APT121-
induced prostate cancer, and isolated APT121;p19Arf
2/2 prostates
exhibited a higher rate of proliferation and no significant
difference in apoptosis compared with APT121;p19Arf
+/+ prostates.
Thus, p19Arf-Mdm2-p53 signaling apparently inhibits APT121-
induced prostate cancer progression by affecting cell proliferation.
Furthermore, the phenotype observed in APT121;p19Arf
2/2 mice
is consistent with that reported in a prior study on APT121;p53
2/2
mice [35], confirming the importance of p19Arf-Mdm2-p53
signaling in tumor suppression of APT121-induced prostate cancer.
In conclusion, the present study suggests that the p19Arf-
Mdm2-p53 pathway suppresses APT121-induced prostate tumor-
igenesis. p19Arf-Mdm2-p53 may be a general pathway to suppress
a wide range of oncogenic insults. However, p19Arf is not required
for p53 response to ribosomal stress, while RP-Mdm2-p53
signaling is required [11]. The lack of ribosomal stress observed
upon pRb inactivation and Ras activation also suggests that the
PR-Mdm2-p53 pathway may not be a general barrier to
oncogenic stress, but rather a specific response to ribosomal stress
induced by oncogenes such as Myc. It is likely that p19Arf and RP
are induced by different cellular conditions, oncogene stress and
ribosomal stress respectively, both resulting in Mdm2 binding and
activation of p53.
Materials and Methods
Ethics Statement
This study is approved by the Institutional Animal Care and
Use Committee at the University of North Carolina at Chapel
Hill. IACUC approval ID. 10–045.0. Mice were humanely
euthanized by CO2 asphyxiation followed by a second method
to ensure euthanasia. Mouse tumors and organs were fixed in
formalin for histopathology and snap frozen for protein extraction.
Mouse Breeding Strategies
Derivation of APT121 (C57BL6/J;DBA2) transgenic mice was
previously described [32]. To study the effect of the RP-Mdm2-p53
pathway on prostate tumorigenesis, APT121 mice were mated to
Mdm2
C305F/C305F (C57BL6/J) mice that were generated and
genotyped as previously described [11]. We used standard breeding
strategies to produce APT121;Mdm2
+/+, APT121;Mdm2
C305F/C305F
and nontransgenic male littermates Mdm2
+/+ and Mdm2
C305F/C305F
served as controls. To study the effect of the p19Arf-Mdm2-p53
pathway on prostate tumorigenesis, APT121 mice were mated to
p19Arf
2/2 (C57BL6/J; Sv129) mice that were generated and
genotyped as previously described [25]. Mice harboring a
homozygous deletion of p19
ARF exon 1 were originally provided
by C. J. Sherr and M. F. Roussel (St. Jude Children’s Hospital) and
maintained in Terry Van Dyke’s lab (UNC-Chapel Hill). We used
standard breeding strategies to produce APT121;p19
ARF+/+ and
APT121;p19
ARF2/2 mice. Mice were bred and maintained under a
protocol (10–045.0) approved by the Institutional Animal Care and
Use Committee at the University of North Carolina Animal Care
Facility. Mice were humanely euthanized by CO2 asphyxiation
followed by a second method to ensure euthanasia. Mouse tumors
and organs were fixed in formalin for histopathology and snap
frozen for protein extraction.
Measurement of prostate size
Prostate tissues from 6 month-old APT121;Mdm2
+/+ and
APT121;Mdm2
C305F/C305F mice as well as from their Mdm2
+/+ and
Mdm2
C305F/C305F littermate controls were excised, photographed,
and weighed. All procedures involving mice were done according
to a protocol approved by the University of North Carolina
Institutional Animal Care and Use Committee.
Table 2. Summary of prostate tumor stages in 5 month-old
APT121;p19Arf
+/+ and APT121;p19Arf
2/2 mice.
APT121;p19Arf
+/+ APT121;p19Arf
2/2
Total 6 6
Epithelial
neoplasia
mPIN 4 0
Adenocarcinoma 2 (33.3%) 6 (100%)
Stromal tumor 0 5 (83.3%)
doi:10.1371/journal.pone.0021625.t002
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21625Figure 3. Effects of p19Arf loss on tumor progression in APT121-induced prostate cancer. A. Representative H&E staining of prostate
sections from 5 month-old mice of the indicated genotypes. Stromal tumor was detected only in APT121;p19Arf
2/2 mice as indicated by asterisk. Scale
bar was shown in the first picture and all pictures were taken at the same magnification. B. Representative Ki67 staining from 5 month-old mice of the
indicated genotypes. Scale bar was shown in the first picture and all pictures were taken at the same magnification. C. Average%Ki67-positive cells 6
SD from 5 month-old mice of the indicated genotypes. n=6 for each genotype. At least five independent fields consisting of a total of at least 1,000
cells from each prostate sample were counted. Brown staining indicates proliferating cells. *p=0.01 as assessed by Student’s t test. D. Representative
TUNEL staining from 5 month-old mice of the indicated genotypes. Scale bar was shown in the first picture and all pictures were taken at the same
magnification. E. Average%TUNEL-positive cells 6 SD from 5 month-old mice of the indicated genotypes. n=6 for each genotype. At least five
independent fields consisting of a total of at least 1,000 cells from each prostate sample were counted. Brown staining indicates apoptotic cells.
doi:10.1371/journal.pone.0021625.g003
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Prostate tissues from APT121;Mdm2
+/+ and APT121;Mdm2
C305F/C305F
mice as well as from their Mdm2
+/+ and Mdm2
C305F/C305F non-
tumorigenic littermate controls, were fixed overnight in
10%phosphate-buffered formalin and then transferred to
70%ethanol. Samples were sent to the UNC Histology Core
Facility for paraffin embedding. Paraffin blocks were sectioned at
5-mm intervals for successive layers and stained with hematoxylin
(Sigma-Aldrich, St. Louis, MO) and eosin for histopathology
examination.
Apoptosis analysis
Apoptosis levels of mouse prostate sections were assessed by the
terminal deoxynucleotidyl transferase–mediated dUTP-biotin nick
end labeling (TUNEL) assay (ApopTaq Peroxidease in situ Kit,
Millipore, Temecula, CA). A ratio of TUNEL-positive stained cells
to total cells counted was calculated. Statistical significance in
differences in apoptosis levels between mice with different
genotypes was evaluated by Student’s t test (P,0.05 was
considered significant).
Proliferation analysis
Ki67 immunohistochemical staining of mouse prostate samples
was used to detect proliferating cells. Antigen retrieval for antibody
on formalin-fixed paraffin sections was done by boiling paraffin
samples in citrate buffer (pH 6.0) for 15 min. Endogenous
peroxidase activity was quenched by incubation in 3%H2O2 in
methanol for 10 minutes. Antibody detection was done by using
purified mouse anti-human Ki67 primary antibody (BD Pharmi-
gen, San Diego, CA) and biotin-conjugated anti-mouse secondary
antibody (Vector Laboratories, Burlingame, CA). An avidin-
biotin-peroxidase kit (Vectastain Elite, Vector Laboratories) with
diaminobenzidine was used as a chromogen. A ratio of positive
stained cells to total cells was calculated. Statistical significance in
differences in proliferation levels between mice with different
genotypes was evaluated by Student’s t test (P,0.05 was
considered significant).
Culture of cells
Mouse keratinocyte cell lines and low-calcium culture media
were provided by Dr. Marcelo Rodriguez-Puebla at North
Figure 4. Activated Ras induces a normal p53 response but does not up-regulate ribosomal protein L11. A. Detection of L11 and b-actin
by immunoblot analysis of total cellular lysate prepared from the indicated mouse karatinocyte cell lines. b-actin serves as a loading control. B.
Representative phase-contrast images of Mdm2
+/+ and Mdm2
C305F/C305F MEFs stably infected with empty vector or H-Ras
G12V retroviruses. C. Detection
of L11, L5, p53, H-Ras, and b-actin by immunoblot analysis of total cellular lysate prepared from the MEFs described in B. b-Actin serves as a loading
control.
doi:10.1371/journal.pone.0021625.g004
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day 13.5 (E 13.5) and cultured in DMEM (GIBCO, Carlsbad, CA)
supplemented with 10%fetal bovine serum (GIBCO) and
penicillin-streptomycin (GIBCO).
Retroviral infection of MEF cells
293 QBT cells [47] were transfected with plasmids: pVPack-Eco
(viral coat protein plasmid for infecting mouse and rat cells),
pVPack-Gag-Pol (viral protein plasmid) and pBabe or pBabe-H-
Ras12V. Fugene HD kit was utilized for transfections, following
manufacturer’s instructions (Roche diagnostics, Indianapolis, IN).
Virus-containing medium from 293 QBT cells was filtered
through a 0.45 mm syringe-tip filter and mixed with fresh medium
at the ratio of 1:1. Polybrene was added to the mixed medium to a
final concentration of 6 mg/ml. The medium from primary mouse
embryo fibroblasts (MEF) cells was removed and replaced with
virus-containing medium. MEF cells were infected with a
retrovirus derived from pBabe-puro-H-Ras12V or empty vector
as a control, and stable polyclonal populations were selected by
puromycin resistance.
Protein detection
Prostate tissues from APT121;Mdm2
+/+ and APT121;Mdm2
C305F/C305F
as well as from their Mdm2
+/+ and Mdm2
C305F/C305F non-tumorigenic
littermate controls were homogenized on ice and lysed in 0.5%NP-40
l y s i sb u f f e r .C u l t u r e dc e l l s( m o u s ek e r a t i n o c y t e sa n dM E F s )w e r ea l s o
lysed in 0.5%NP-40 lysis buffer. Total cellular lysates were run on a
12.5%SDS-polyacrymide gel followed by immunoblotting using
standard procedures. Mouse monoclonal anti-p53 (NCL-505, Novo-
castra Laboratories, Newcastle upon Tyne, England) and anti-actin
(MAB1501, Chemicon International, Temecula, CA) antibodies were
purchased commercially. Rabbit polyclonal antibodies to L5 and L11
were produced as previously described [10].
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